Combination Therapy Boosts Survival Rates in Aggressive Prostate Cancer by 40%
A landmark study published in NEJM shows that pairing Leuprolide and Enzalutamide significantly increases survival rates for men with high-risk, recurring prostate cancer, emphasizing early detection, proactive treatment, and lifestyle management to improve quality of life.